Liver activation nanoemulsion and toxin excretion enhancement method

A method of making an intra-oral, nanoemulsion blend for enhancing liver performance in animals when orally administered, the method comprising:

• forming a mixture comprising milk thistle extract, an amphiphilic fat including at least 30% by weight phosphatidylcholine, a polyethylene glycol surfactant, an associating oil, glycerin, ethanol, and water to form a first emulsion,
• where the first emulsion has a ratio of the amphiphilic fat to the polyethylene glycol surfactant from 1:1.8 to 1:3 by weight;
• forming a mixture comprising an amphiphilic fat including at least 30% by weight phosphatidylcholine, a polyethylene glycol surfactant, an associating oil, glycerin, ethanol, and water to form a second emulsion including liposomes;
• combining the first and second emulsions with R-Lipoic acid sodium salt to form a third emulsion;
• combining the third emulsion with additional ethanol and glycerin to form a fourth emulsion;
• and
• adding additional water to the fourth emulsion while stirring at room temperature and pressure to form a stable dispersion that is transparent, where particles of the blend have an average diameter from 10 to 100 nanometers.

A liver detoxification method for an animal, comprising:

• holding from 4 to 6 milliliters of a nanoemulsion blend under the tongue of an animal from 30 seconds to 2 minutes, where the nanoemulsion blend comprises
• at least one monolayer surfactant bound particle, where
• the at least one monolayer surfactant bound particle comprises at least one amphiphilic fat, a polyethylene glycol surfactant form, an associating oil, and milk thistle;
• at least one bilayer liposome, where
• the at least one bilayer liposome comprises the at least one amphiphilic fat and the polyethylene glycol surfactant forming a capsule, where an interior of the capsule includes myrrh dissolved in water, ethanol, and glycerin;
• and
• a continuous phase comprising water, ethanol, and glycerin;
• where
• the at least one amphiphilic fat is associated with R-Lipoic acid,
• the blend is a stable dispersion that is transparent, and
• the at least one monolayer surfactant bound particle and the at least one bilayer liposome have an average particle diameter from 10 to 100 nanometers as carried by the continuous phase;
• waiting from approximately 20 minutes to 40 minutes;
• consuming from 2 to 6 grams of a solid powder toxin binding composition suspended in water, where the solid powder toxin binding composition comprises a thiol-functionalized silica binder, a zeolite binder, an activated charcoal binder, a bentonite clay binder, a chitosan binder, a mucosal lining repair agent, and a mucosal lining lubricating agent;
• and
• excreting the solid powder toxin binding composition.